{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:35:35Z","timestamp":1789180535893,"version":"build-2803163510"},"reference-count":127,"publisher":"Elsevier","isbn-type":[{"value":"9780443313967","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004462","name":"Consiglio Nazionale delle Ricerche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004462","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.enz.2025.07.005","type":"book-chapter","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:40:57Z","timestamp":1759009257000},"page":"183-208","source":"Crossref","is-referenced-by-count":1,"title":["Coronaviruses main proteases and their inhibitors"],"prefix":"10.1016","author":[{"given":"Claudiu T.","family":"Supuran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemente","family":"Capasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/bs.enz.2025.07.005_bib0001","doi-asserted-by":"crossref","first-page":"337","DOI":"10.36740\/Merkur202403111","article-title":"A review on the current approaches and perspectives of Covid-19 treatment","volume":"52","author":"Dobrek","year":"2024","journal-title":"Pol. Merkur. Lekarski"},{"issue":"2","key":"10.1016\/bs.enz.2025.07.005_bib0002","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s12325-024-03043-0","article-title":"Is COVID-19 still a threat? An expert opinion review on the continued healthcare burden in immunocompromised individuals","volume":"42","author":"Spinner","year":"2025","journal-title":"Adv. Ther"},{"issue":"4","key":"10.1016\/bs.enz.2025.07.005_bib0003","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00431-023-05360-y","article-title":"Long COVID in pediatrics-epidemiology, diagnosis, and management","volume":"183","author":"Toepfner","year":"2024","journal-title":"Eur. J. Pediatr"},{"key":"10.1016\/bs.enz.2025.07.005_bib0004","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.15.04141","article-title":"Risk factors for severe COVID-19 outcomes in LATAM countries in the post-vaccination era: an analysis of national surveillance data in Argentina, Brazil, Colombia, and Mexico","volume":"15","author":"Julian","year":"2025","journal-title":"J. Glob. Health"},{"issue":"5","key":"10.1016\/bs.enz.2025.07.005_bib0005","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.70379","article-title":"Comparative analysis of early COVID-19 treatment efficacy in a multicentric regional cohort in Italy: emulation of a series of target trials","volume":"97","author":"Mazzotta","year":"2025","journal-title":"J. Med. Virol"},{"issue":"1","key":"10.1016\/bs.enz.2025.07.005_bib0006","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/AOG.0000000000005904","article-title":"Coronavirus disease 2019 (COVID-19) vaccination and spontaneous abortion","volume":"146","author":"Sheth","year":"2025","journal-title":"Obstet. Gynecol"},{"issue":"11","key":"10.1016\/bs.enz.2025.07.005_bib0007","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.3390\/vaccines12111220","article-title":"Combating emerging respiratory viruses: lessons and future antiviral strategies","volume":"12","author":"Muthukutty","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"10.1016\/bs.enz.2025.07.005_bib0008","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s40259-023-00611-8","article-title":"Staying ahead of the game: how SARS-CoV-2 has accelerated the application of machine learning in pandemic management","volume":"37","author":"Williams","year":"2023","journal-title":"BioDrugs"},{"issue":"17","key":"10.1016\/bs.enz.2025.07.005_bib0009","doi-asserted-by":"crossref","first-page":"eadt7836","DOI":"10.1126\/sciadv.adt7836","article-title":"Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus M(Pro) inhibitors with potent in vivo efficacy","volume":"11","author":"Detomasi","year":"2025","journal-title":"Sci. Adv"},{"issue":"10","key":"10.1016\/bs.enz.2025.07.005_bib0010","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00044-022-02951-6","article-title":"The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations","volume":"31","author":"Joyce","year":"2022","journal-title":"Med. Chem. Res"},{"issue":"2","key":"10.1016\/bs.enz.2025.07.005_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2025.e41980","article-title":"SARS-CoV-2 drug resistance and therapeutic approaches","volume":"11","author":"Batool","year":"2025","journal-title":"Heliyon"},{"issue":"5","key":"10.1016\/bs.enz.2025.07.005_bib0012","first-page":"487","article-title":"What is the role of remdesivir in patients with COVID-19?","volume":"27","author":"Beigel","year":"2021","journal-title":"Curr. Opin. Crit. Care"},{"issue":"9","key":"10.1016\/bs.enz.2025.07.005_bib0013","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1038\/s41591-023-02503-4","article-title":"Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial","volume":"29","author":"Branche","year":"2023","journal-title":"Nat. Med"},{"issue":"4","key":"10.1016\/bs.enz.2025.07.005_bib0014","first-page":"11","article-title":"Study of efficacy of injection remdesivir in patients of COVID-19","volume":"71","author":"Chaudhary","year":"2023","journal-title":"J. Assoc. Phys. Ind."},{"key":"10.1016\/bs.enz.2025.07.005_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112527","article-title":"A promising antiviral candidate drug for the COVID-19 pandemic: a mini-review of remdesivir","volume":"201","author":"Liang","year":"2020","journal-title":"Eur. J. Med. Chem"},{"issue":"1","key":"10.1016\/bs.enz.2025.07.005_bib0016","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1021\/acs.jproteome.0c00526","article-title":"Overview of targets and potential drugs of SARS-CoV-2 according to the viral replication","volume":"20","author":"Zhang","year":"2021","journal-title":"J. Proteome Res"},{"key":"10.1016\/bs.enz.2025.07.005_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"Coronaviruses: An overview of their replication and pathogenesis","volume":"1282","author":"Fehr","year":"2015","journal-title":"Methods Mol. Biol"},{"key":"10.1016\/bs.enz.2025.07.005_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-0716-0900-2_1","article-title":"Coronaviruses: An updated overview of their replication and pathogenesis","volume":"2203","author":"Wang","year":"2020","journal-title":"Methods Mol. Biol"},{"key":"10.1016\/bs.enz.2025.07.005_bib0019","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.csbj.2020.08.002","article-title":"ACE2 enhance viral infection or viral infection aggravate the underlying diseases","volume":"18","author":"Teng","year":"2020","journal-title":"Comput. Struct. Biotechnol. J"},{"issue":"1","key":"10.1016\/bs.enz.2025.07.005_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2022.152302","article-title":"A review on structural, non-structural, and accessory proteins of SARS-CoV-2: highlighting drug target sites","volume":"228","author":"Jahirul Islam","year":"2023","journal-title":"Immunobiology"},{"issue":"1","key":"10.1016\/bs.enz.2025.07.005_bib0021","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41392-022-00884-5","article-title":"Structural biology of SARS-CoV-2: open the door for novel therapies","volume":"7","author":"Yan","year":"2022","journal-title":"Signal Transduct. Target Ther"},{"issue":"11","key":"10.1016\/bs.enz.2025.07.005_bib0022","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41579-021-00630-8","article-title":"Structural biology of SARS-CoV-2 and implications for therapeutic development","volume":"19","author":"Yang","year":"2021","journal-title":"Nat. Rev. Micro."},{"issue":"3","key":"10.1016\/bs.enz.2025.07.005_bib0023","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"V'Kovski","year":"2021","journal-title":"Nat. Rev. Micro."},{"key":"10.1016\/bs.enz.2025.07.005_bib0024","doi-asserted-by":"crossref","DOI":"10.1177\/11779322211025876","article-title":"Structure and function of major SARS-CoV-2 and SARS-CoV proteins","volume":"15","author":"Gorkhali","year":"2021","journal-title":"Bioinform. Biol. Insights"},{"issue":"16","key":"10.1016\/bs.enz.2025.07.005_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241613002","article-title":"Targeting SARS-CoV-2 Non-Structural Proteins","volume":"24","author":"Tam","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"10.1016\/bs.enz.2025.07.005_bib0026","doi-asserted-by":"crossref","first-page":"10280","DOI":"10.1128\/JVI.00017-07","article-title":"Processing of open reading frame 1a replicase proteins nsp7 to nsp10 in murine hepatitis virus strain A59 replication","volume":"81","author":"Deming","year":"2007","journal-title":"J. Virol"},{"issue":"6","key":"10.1016\/bs.enz.2025.07.005_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107367","article-title":"Kinetic comparison of all eleven viral polyprotein cleavage site processing events by SARS-CoV-2 main protease using a linked protein FRET platform","volume":"300","author":"Kenward","year":"2024","journal-title":"J. Biol. Chem"},{"issue":"24","key":"10.1016\/bs.enz.2025.07.005_bib0028","doi-asserted-by":"crossref","first-page":"15199","DOI":"10.1128\/JVI.79.24.15199-15208.2005","article-title":"The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme","volume":"79","author":"Lindner","year":"2005","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/bs.enz.2025.07.005_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011065","article-title":"Ubiquitin variants potently inhibit SARS-CoV-2 PLpro and viral replication via a novel site distal to the protease active site","volume":"18","author":"van Vliet","year":"2022","journal-title":"PLoS Pathog"},{"issue":"1","key":"10.1016\/bs.enz.2025.07.005_bib0030","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41467-021-21060-3","article-title":"Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors","volume":"12","author":"Osipiuk","year":"2021","journal-title":"Nat. Commun"},{"issue":"Pt 1","key":"10.1016\/bs.enz.2025.07.005_bib0031","first-page":"267","article-title":"SARS-CoV-2 Mpro oligomerization as a potential target for therapy","author":"Lis","year":"2024","journal-title":"Int. J. Biol. Macromol"},{"issue":"4","key":"10.1016\/bs.enz.2025.07.005_bib0032","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3390\/biom11040607","article-title":"SARS-CoV-2 M(pro): a potential target for peptidomimetics and small-molecule inhibitors","volume":"11","author":"Citarella","year":"2021","journal-title":"Biomolecules"},{"issue":"11","key":"10.1016\/bs.enz.2025.07.005_bib0033","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.peptides.2004.06.018","article-title":"Polyprotein cleavage mechanism of SARS CoV Mpro and chemical modification of the octapeptide","volume":"25","author":"Du","year":"2004","journal-title":"Peptides"},{"key":"10.1016\/bs.enz.2025.07.005_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1251705","article-title":"Characterization of host substrates of SARS-CoV-2 main protease","volume":"14","author":"Melano","year":"2023","journal-title":"Front. Microbiol"},{"issue":"9","key":"10.1016\/bs.enz.2025.07.005_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012522","article-title":"A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system","volume":"20","author":"Costacurta","year":"2024","journal-title":"PLoS Pathog"},{"issue":"14","key":"10.1016\/bs.enz.2025.07.005_bib0036","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","article-title":"An overview of severe acute respiratory syndrome-coronavirus (sars-cov) 3cl protease inhibitors: peptidomimetics and small molecule chemotherapy","volume":"59","author":"Pillaiyar","year":"2016","journal-title":"J. Med. Chem"},{"issue":"3","key":"10.1016\/bs.enz.2025.07.005_bib0037","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1002\/mco2.151","article-title":"The SARS-CoV-2 main protease (M(pro)): structure, function, and emerging therapies for COVID-19","volume":"3","author":"Hu","year":"2020","journal-title":"MedComm"},{"issue":"6","key":"10.1016\/bs.enz.2025.07.005_bib0038","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1021\/acsinfecdis.0c00815","article-title":"Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19","volume":"7","author":"Steuten","year":"2021","journal-title":"ACS Infect. Dis"},{"issue":"7","key":"10.1016\/bs.enz.2025.07.005_bib0039","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3390\/biom14070797","article-title":"Inhibitors of SARS-CoV-2 main protease (Mpro) as anti-coronavirus agents","volume":"14","author":"Zagorska","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/bs.enz.2025.07.005_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.692168","article-title":"Catalytic dyad residues His41 and Cys145 impact the catalytic activity and overall conformational fold of the main SARS-CoV-2 protease 3-chymotrypsin-like protease","volume":"9","author":"Ferreira","year":"2021","journal-title":"Front Chem"},{"key":"10.1016\/bs.enz.2025.07.005_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115772","article-title":"Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: a comprehensive review","volume":"260","author":"Li","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/bs.enz.2025.07.005_bib0042","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3390\/v16060844","article-title":"3-chymotrypsin-like protease (3CLpro) of SARS-CoV-2: validation as a molecular target, proposal of a novel catalytic mechanism, and inhibitors in preclinical and clinical trials","volume":"16","author":"Amorim","year":"2024","journal-title":"Viruses-Basel"},{"issue":"7","key":"10.1016\/bs.enz.2025.07.005_bib0043","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1021\/acschembio.4c00096","article-title":"High-resolution substrate specificity profiling of SARS-CoV-2 M(pro); comparison to SARS-CoV M(pro)","volume":"19","author":"Yaghi","year":"2024","journal-title":"ACS Chem Biol"},{"issue":"3","key":"10.1016\/bs.enz.2025.07.005_bib0044","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3390\/ph15030308","article-title":"In Silico and in vitro identification of pan-coronaviral main protease inhibitors from a large natural product library","volume":"15","author":"Shahhamzehei","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"17","key":"10.1016\/bs.enz.2025.07.005_bib0045","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1021\/bi0361766","article-title":"Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro","volume":"43","author":"Bacha","year":"2004","journal-title":"Biochemistry"},{"issue":"5","key":"10.1016\/bs.enz.2025.07.005_bib0046","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3390\/ph17050650","article-title":"New thiazolidine-4-One derivatives as SARS-CoV-2 main protease inhibitors","volume":"17","author":"Messore","year":"2024","journal-title":"Pharmaceuticals-Base"},{"issue":"11","key":"10.1016\/bs.enz.2025.07.005_bib0047","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1248\/bpb.b24-00369","article-title":"Sunflower trypsin monocyclic inhibitor selected for the main protease of SARS-CoV-2 by phage display","volume":"47","author":"Ferreira","year":"2024","journal-title":"Biol. Pharm. Bull"},{"issue":"6","key":"10.1016\/bs.enz.2025.07.005_bib0048","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1021\/acsptsci.0c00130","article-title":"Ebselen, Carmofur Disulfiram, PX-12, tideglusib, and shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors","volume":"3","author":"Ma","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"1","key":"10.1016\/bs.enz.2025.07.005_bib0049","first-page":"182","article-title":"The pathogenicity of MERS-CoV, SARS-CoV and SARS-CoV-2: a comparative overview","volume":"16","author":"Shashank","year":"2021","journal-title":"Res. J. Biotechnol"},{"issue":"8","key":"10.1016\/bs.enz.2025.07.005_bib0050","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.02013-21","article-title":"Structural basis of the main proteases of coronavirus bound to drug candidate PF-07321332","volume":"96","author":"Li","year":"2022","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/bs.enz.2025.07.005_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165878","article-title":"Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach","volume":"1866","author":"Naqvi","year":"2020","journal-title":"Bba-Mol. Basis Dis."},{"key":"10.1016\/bs.enz.2025.07.005_bib0052","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.virol.2023.02.011","article-title":"Genetic conservation across SARS-CoV-2 non-structural proteins-insights into possible targets for treatment of future viral outbreaks","volume":"581","author":"Kandwal","year":"2023","journal-title":"Virology"},{"issue":"1","key":"10.1016\/bs.enz.2025.07.005_bib0053","doi-asserted-by":"crossref","first-page":"7055","DOI":"10.1038\/s41598-023-34305-6","article-title":"Structural analysis of the coronavirus main protease for the design of pan-variant inhibitors","volume":"13","author":"Rungruangmaitree","year":"2023","journal-title":"Sci. Rep"},{"issue":"8","key":"10.1016\/bs.enz.2025.07.005_bib0054","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1021\/jacsau.4c00508","article-title":"A structural comparison of oral SARS-CoV-2 drug candidate ibuzatrelvir complexed with the main protease (M(pro)) of SARS-CoV-2 and MERS-CoV","volume":"4","author":"Chen","year":"2024","journal-title":"JACS Au"},{"issue":"6","key":"10.1016\/bs.enz.2025.07.005_bib0055","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1021\/acs.jcim.1c00449","article-title":"Dynamic profiling of \u03b2-coronavirus 3CL Mpro protease ligand-binding sites","volume":"61","author":"Cho","year":"2021","journal-title":"J. Chem. Inf. Model"},{"issue":"3","key":"10.1016\/bs.enz.2025.07.005_bib0056","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1021\/acsptsci.0c00215","article-title":"A blueprint for high affinity SARS-CoV-2 Mpro inhibitors from activity-based compound library screening guided by analysis of protein dynamics","volume":"4","author":"Gossen","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/bs.enz.2025.07.005_bib0057","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.77433","article-title":"Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms","volume":"11","author":"Flynn","year":"2022","journal-title":"eLife"},{"key":"10.1016\/bs.enz.2025.07.005_bib0058","first-page":"1","article-title":"Structural differences in 3C-like protease (Mpro) from SARS-CoV and SARS-CoV-2: molecular insights revealed by Molecular Dynamics Simulations","author":"Parmar","year":"2022","journal-title":"Struct. Chem."},{"issue":"4","key":"10.1016\/bs.enz.2025.07.005_bib0059","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/iub.2465","article-title":"Identification of mutation resistance coldspots for targeting the SARS-CoV2 main protease","volume":"73","author":"Krishnamoorthy","year":"2021","journal-title":"IUBMB Life"},{"issue":"1","key":"10.1016\/bs.enz.2025.07.005_bib0060","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/s41467-025-56651-x","article-title":"Distal protein-protein interactions contribute to SARS-CoV-2 main protease substrate binding and nirmatrelvir resistance","volume":"16","author":"Lewandowski","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/bs.enz.2025.07.005_bib0061","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/s41467-025-56651-x","article-title":"Distal protein-protein interactions contribute to nirmatrelvir resistance","volume":"16","author":"Lewandowski","year":"2025","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/bs.enz.2025.07.005_bib0062","doi-asserted-by":"crossref","first-page":"e0406824","DOI":"10.1128\/mbio.04068-24","article-title":"Molecular mechanisms of drug resistance and compensation in SARS-CoV-2 main protease: the interplay between E166 and L50","volume":"16","author":"Zvornicanin","year":"2025","journal-title":"mBio"},{"issue":"4","key":"10.1016\/bs.enz.2025.07.005_bib0063","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/13543776.2021.1857726","article-title":"Protease inhibitors targeting the main protease and papain-like protease of coronaviruses","volume":"31","author":"Capasso","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"issue":"2","key":"10.1016\/bs.enz.2025.07.005_bib0064","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3390\/ijms25020971","article-title":"Leveraging SARS-CoV-2 main protease (M(pro)) for COVID-19 mitigation with selenium-based inhibitors","volume":"25","author":"De Luca","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/bs.enz.2025.07.005_bib0065","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1080\/14756366.2021.1924165","article-title":"Is carbonic anhydrase inhibition useful as a complementary therapy of Covid-19 infection?","volume":"36","author":"Deniz","year":"2021","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"7","key":"10.1016\/bs.enz.2025.07.005_bib0066","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/13543776.2020.1760838","article-title":"A deadly spillover: SARS-CoV-2 outbreak","volume":"30","author":"Mori","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"issue":"6","key":"10.1016\/bs.enz.2025.07.005_bib0067","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/17460441.2022.2052847","article-title":"Perspectives on the design and discovery of alpha-ketoamide inhibitors for the treatment of novel coronavirus: where do we stand and where do we go?","volume":"17","author":"Nocentini","year":"2022","journal-title":"Expert Opin. Drug Discov."},{"issue":"1","key":"10.1016\/bs.enz.2025.07.005_bib0068","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1021\/acsptsci.2c00203","article-title":"Detailed insights into the inhibitory mechanism of new ebselen derivatives against Main protease (Mpro) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)","volume":"6","author":"Sahoo","year":"2022","journal-title":"ACS Pharmacol. Transl."},{"issue":"11","key":"10.1016\/bs.enz.2025.07.005_bib0069","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00840-23","article-title":"Evaluation of in vitro antiviral activity of SARS-CoV-2 M(pro) inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions","volume":"67","author":"Tong","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/bs.enz.2025.07.005_bib0070","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2217\/fvl.09.1","article-title":"Advances in antiviral drug discovery and development: Part II: advancements in antiviral drug development","volume":"4","author":"Saxena","year":"2009","journal-title":"Fut. Virol."},{"issue":"2","key":"10.1016\/bs.enz.2025.07.005_bib0071","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2217\/17460794.4.2.101","article-title":"Advances in antiviral drug discovery and development: Part I: advancements in antiviral drug discovery","volume":"4","author":"Saxena","year":"2009","journal-title":"Fut. Virol."},{"issue":"11","key":"10.1016\/bs.enz.2025.07.005_bib0072","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1021\/acs.jmedchem.5b01697","article-title":"Recent progress in the development of HIV-1 protease inhibitors for the Treatment of HIV\/AIDS","volume":"59","author":"Ghosh","year":"2016","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/bs.enz.2025.07.005_bib0073","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1002\/jmv.26814","article-title":"Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19","volume":"93","author":"Anirudhan","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/bs.enz.2025.07.005_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2022.101159","article-title":"Viral proteases as therapeutic targets","volume":"88","author":"Majerov\u00e1","year":"2022","journal-title":"Mol. Aspects Med"},{"issue":"1","key":"10.1016\/bs.enz.2025.07.005_bib0075","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/biomedicines11010085","article-title":"Potential inhibitors of SARS-CoV-2 Main Protease (M(pro)) identified from the Library of FDA-approved drugs using molecular docking studies","volume":"11","author":"Verma","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/bs.enz.2025.07.005_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100026","article-title":"Systematic review on role of structure based drug design (SBDD) in the identification of anti-viral leads against SARS-Cov-2","volume":"2","author":"Bajad","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Discov"},{"issue":"9","key":"10.1016\/bs.enz.2025.07.005_bib0077","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3390\/biom13091339","article-title":"Recent advances in SARS-CoV-2 main protease inhibitors: from nirmatrelvir to future Perspectives","volume":"13","author":"Citarella","year":"2023","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/bs.enz.2025.07.005_bib0078","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40262-023-01339-y","article-title":"A comprehensive review of the clinical pharmacokinetics, pharmacodynamics, and drug interactions of nirmatrelvir\/ritonavir","volume":"63","author":"Gerhart","year":"2024","journal-title":"Clin. Pharmacokinet"},{"key":"10.1016\/bs.enz.2025.07.005_bib0079","doi-asserted-by":"crossref","first-page":"114367","DOI":"10.1016\/j.biopha.2023.114367","article-title":"Paxlovid (Nirmatrelvir\/Ritonavir): A new approach to Covid-19 therapy?","volume":"162","author":"Hashemian","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/bs.enz.2025.07.005_bib0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/d41573-021-00202-8","article-title":"A tale of two antiviral targets\u2014and the COVID-19 drugs that bind them","volume":"21","author":"Cully","year":"2022","journal-title":"Nat. Rev. Drug Discov"},{"issue":"1","key":"10.1016\/bs.enz.2025.07.005_bib0081","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1021\/acsbiomedchemau.4c00109","article-title":"Exploring possible drug-resistant variants of SARS-CoV-2 main protease (M(pro)) with noncovalent preclinical candidate, Mpro61","volume":"5","author":"Kenneson","year":"2025","journal-title":"ACS Bio. Med. Chem. Au"},{"key":"10.1016\/bs.enz.2025.07.005_bib0082","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.coviro.2021.04.006","article-title":"Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection","volume":"49","author":"Vandyck","year":"2021","journal-title":"Curr. Opin. Virol"},{"key":"10.1016\/bs.enz.2025.07.005_bib0083","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.omtn.2023.03.013","article-title":"Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?","volume":"32","author":"Chatterjee","year":"2023","journal-title":"Mol. Ther-Nucl. Acids"},{"issue":"6","key":"10.1016\/bs.enz.2025.07.005_bib0084","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrgastro.2016.60","article-title":"Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights","volume":"13","author":"Gotte","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol"},{"issue":"9","key":"10.1016\/bs.enz.2025.07.005_bib0085","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1128\/AAC.00498-08","article-title":"Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance","volume":"52","author":"Mathy","year":"2008","journal-title":"Antimicrob. Agents Chemother"},{"issue":"2","key":"10.1016\/bs.enz.2025.07.005_bib0086","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1021\/acs.jmedchem.1c00302","article-title":"Kinase inhibitors as underexplored antiviral agents","volume":"65","author":"Garc\u00eda-C\u00e1rceles","year":"2022","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/bs.enz.2025.07.005_bib0087","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1021\/acs.molpharmaceut.4c00256","article-title":"Application of mechanistic multiparameter optimization and large-scale in vitro to in vivo pharmacokinetics correlations to small-molecule therapeutic projects","volume":"21","author":"Broccatelli","year":"2024","journal-title":"Mol. Pharm"},{"issue":"4","key":"10.1016\/bs.enz.2025.07.005_bib0088","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/fcp.12989","article-title":"Population pharmacokinetics and pharmacodynamics of nirmatrelvir in Chinese patients with COVID-19","volume":"38","author":"Zeng","year":"2024","journal-title":"Fundam. Clin. Pharmacol"},{"issue":"6","key":"10.1016\/bs.enz.2025.07.005_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103579","article-title":"COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease","volume":"28","author":"Kronenberger","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/bs.enz.2025.07.005_bib0090","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2147\/DDDT.S359009","article-title":"Progress on SARS-CoV-2 3CLpro inhibitors: inspiration from SARS-CoV 3CLpro peptidomimetics and small-molecule anti-inflammatory compounds","volume":"16","author":"Zhu","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"issue":"8","key":"10.1016\/bs.enz.2025.07.005_bib0091","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res"},{"issue":"11","key":"10.1016\/bs.enz.2025.07.005_bib0092","doi-asserted-by":"crossref","first-page":"8757","DOI":"10.1021\/acs.jmedchem.4c00053","article-title":"Macrocyclic azapeptide nitriles: structure-based discovery of potent SARS-CoV-2 main protease inhibitors as antiviral drugs","volume":"67","author":"Breidenbach","year":"2024","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/bs.enz.2025.07.005_bib0093","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.3390\/molecules27082561","article-title":"Covalent reversible inhibitors of cysteine proteases containing the nitrile warhead: recent advancement in the field of viral and parasitic diseases","volume":"27","author":"Brogi","year":"2022","journal-title":"Molecules"},{"issue":"10","key":"10.1016\/bs.enz.2025.07.005_bib0094","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1039\/D1MD00247C","article-title":"Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors","volume":"12","author":"Bai","year":"2021","journal-title":"Rsc. Med. Chem."},{"issue":"14","key":"10.1016\/bs.enz.2025.07.005_bib0095","doi-asserted-by":"crossref","first-page":"11656","DOI":"10.1021\/acs.jmedchem.4c01342","article-title":"Fixing the Achilles Heel of Pfizer\u2019s Paxlovid for COVID-19 treatment","volume":"67","author":"Brewitz","year":"2024","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/bs.enz.2025.07.005_bib0096","doi-asserted-by":"crossref","first-page":"13550","DOI":"10.1021\/acs.jmedchem.3c02469","article-title":"A second-generation oral SARS-CoV-2 main protease inhibitor clinical candidate for the treatment of COVID-19","volume":"67","author":"Allerton","year":"2024","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/bs.enz.2025.07.005_bib0097","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1021\/acs.jmedchem.2c01627","article-title":"Alkyne derivatives of SARS-CoV-2 main protease inhibitors including nirmatrelvir inhibit by reacting covalently with the nucleophilic cysteine","volume":"66","author":"Brewitz","year":"2023","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/bs.enz.2025.07.005_bib0098","doi-asserted-by":"crossref","first-page":"12237","DOI":"10.1021\/acs.jmedchem.3c00810","article-title":"Alkyne as a latent warhead to covalently target SARS-CoV-2 main protease","volume":"66","author":"Ngo","year":"2023","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/bs.enz.2025.07.005_bib0099","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1038\/s41467-020-19339-y","article-title":"Author correction: feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication","volume":"11","author":"Vuong","year":"2020","journal-title":"Nat. Commun"},{"key":"10.1016\/bs.enz.2025.07.005_bib0100","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.852210","article-title":"Crystallization of Feline Coronavirus M(pro) With GC376 Reveals Mechanism of Inhibition","volume":"10","author":"Lu","year":"2022","journal-title":"Front. Chem"},{"issue":"1","key":"10.1016\/bs.enz.2025.07.005_bib0101","article-title":"MPI8 is Potent against SARS-CoV-2 by inhibiting dually and selectively the SARS-CoV-2 main protease and the host Cathepsin L**","volume":"17","author":"Ma","year":"2022","journal-title":"ChemMedChem"},{"issue":"19","key":"10.1016\/bs.enz.2025.07.005_bib0102","doi-asserted-by":"crossref","first-page":"13328","DOI":"10.1021\/acs.jmedchem.2c01131","article-title":"Diastereomeric resolution yields highly potent inhibitor of SARS-CoV-2 main protease","volume":"65","author":"Cooper","year":"2022","journal-title":"J. Med. Chem"},{"issue":"4","key":"10.1016\/bs.enz.2025.07.005_bib0103","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2174\/0929867003375074","article-title":"Orally active peptidomimetic RGD analogs that are glycoprotein IIb\/IIIa antagonists","volume":"7","author":"Wang","year":"2000","journal-title":"Curr. Med. Chem"},{"issue":"1","key":"10.1016\/bs.enz.2025.07.005_bib0104","first-page":"48","article-title":"Lipid-based nanoparticles as oral drug delivery systems: overcoming poor gastrointestinal absorption and enhancing bioavailability of peptide and protein therapeutics","volume":"14","author":"Mehrdadi","year":"2024","journal-title":"Adv. Pharm. Bull"},{"issue":"738","key":"10.1016\/bs.enz.2025.07.005_bib0105","doi-asserted-by":"crossref","first-page":"eadi0979","DOI":"10.1126\/scitranslmed.adi0979","article-title":"An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations","volume":"16","author":"Westberg","year":"2024","journal-title":"Sci. Transl. Med"},{"issue":"1","key":"10.1016\/bs.enz.2025.07.005_bib0106","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1038\/s41467-021-23751-3","article-title":"Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease","volume":"12","author":"Su","year":"2021","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/bs.enz.2025.07.005_bib0107","doi-asserted-by":"crossref","first-page":"e4712","DOI":"10.1002\/pro.4712","article-title":"Large library docking for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors","volume":"32","author":"Fink","year":"2023","journal-title":"Protein Sci"},{"issue":"4","key":"10.1016\/bs.enz.2025.07.005_bib0108","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1021\/acs.jmedchem.1c00509","article-title":"Expedited approach toward the rational design of noncovalent SARS-CoV-2 main protease inhibitors","volume":"65","author":"Kitamura","year":"2022","journal-title":"J. Med. Chem"},{"issue":"9","key":"10.1016\/bs.enz.2025.07.005_bib0109","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J. Med. Chem"},{"issue":"6","key":"10.1016\/bs.enz.2025.07.005_bib0110","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20201256","article-title":"Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy","volume":"40","author":"Shamsi","year":"2020","journal-title":"Biosci. Rep"},{"issue":"11","key":"10.1016\/bs.enz.2025.07.005_bib0111","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.1021\/jm500345q","article-title":"A fragment-based method to discover irreversible covalent inhibitors of cysteine proteases","volume":"57","author":"Kathman","year":"2014","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/bs.enz.2025.07.005_bib0112","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/1878-0261.13277","article-title":"Fragment-based drug discovery-the importance of high-quality molecule libraries","volume":"16","author":"Bon","year":"2022","journal-title":"Mol. Oncol"},{"issue":"5","key":"10.1016\/bs.enz.2025.07.005_bib0113","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1042\/EBC20170029","article-title":"Fragment-based drug discovery and its application to challenging drug targets","volume":"61","author":"Price","year":"2017","journal-title":"Essays Biochem"},{"issue":"7","key":"10.1016\/bs.enz.2025.07.005_bib0114","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1021\/acs.jmedchem.7b00411","article-title":"Correction to fragment-linking approach using (19)F NMR spectroscopy to obtain highly potent and selective inhibitors of beta-secretase","volume":"60","author":"Jordan","year":"2017","journal-title":"J. Med. Chem"},{"issue":"43","key":"10.1016\/bs.enz.2025.07.005_bib0115","article-title":"Miniaturized modular click chemistry-enabled rapid discovery of unique SARS-CoV-2 M(pro) inhibitors with robust potency and drug-like profile","volume":"11","author":"Yang","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"issue":"35","key":"10.1016\/bs.enz.2025.07.005_bib0116","doi-asserted-by":"crossref","first-page":"eadj3010","DOI":"10.1126\/sciadv.adj3010","article-title":"Accelerating drug discovery and repurposing by combining transcriptional signature connectivity with docking","volume":"10","author":"Thorman","year":"2024","journal-title":"Sci. Adv."},{"issue":"7","key":"10.1016\/bs.enz.2025.07.005_bib0117","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1021\/acsinfecdis.3c00125","article-title":"Systematic Analyses of the resistance potential of drugs targeting SARS-CoV-2 main protease","volume":"9","author":"Flynn","year":"2023","journal-title":"ACS Infect. Dis"},{"issue":"4","key":"10.1016\/bs.enz.2025.07.005_bib0118","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1021\/acsinfecdis.3c00560","article-title":"Contributions of Hyperactive Mutations in M(pro) from SARS-CoV-2 to drug resistance","volume":"10","author":"Flynn","year":"2024","journal-title":"ACS Infect. Dis."},{"issue":"8","key":"10.1016\/bs.enz.2025.07.005_bib0119","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1021\/acscentsci.3c00538","article-title":"Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir","volume":"9","author":"Hu","year":"2023","journal-title":"ACS Cent. Sci"},{"key":"10.1016\/bs.enz.2025.07.005_bib0120","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1192832","article-title":"Viable SARS-CoV-2 Omicron sub-variants isolated from autopsy tissues","volume":"14","author":"Maffia-Bizzozero","year":"2023","journal-title":"Front Microbiol"},{"issue":"12","key":"10.1016\/bs.enz.2025.07.005_bib0121","doi-asserted-by":"crossref","first-page":"6715","DOI":"10.3390\/ijms25126715","article-title":"Rational approach toward COVID-19\u2019s main protease inhibitors: a hierarchical biochemoinformatics analysis","volume":"25","author":"Bastos","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/bs.enz.2025.07.005_bib0122","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1021\/acs.jpcb.4c07920","article-title":"In silico discovery of SARS-CoV-2 main protease inhibitors using docking, molecular dynamics, and fragment molecular orbital calculations","volume":"129","author":"Ishikawa","year":"2025","journal-title":"J. Phys. Chem. B"},{"issue":"23","key":"10.1016\/bs.enz.2025.07.005_bib0123","doi-asserted-by":"crossref","first-page":"16922","DOI":"10.1021\/acs.jmedchem.1c00409","article-title":"Perspectives on SARS-CoV-2 main protease inhibitors","volume":"64","author":"Gao","year":"2021","journal-title":"J. Med. Chem"},{"issue":"19","key":"10.1016\/bs.enz.2025.07.005_bib0124","doi-asserted-by":"crossref","first-page":"12500","DOI":"10.1021\/acs.jmedchem.2c01005","article-title":"Targeting SARS-CoV-2 main protease for treatment of COVID-19: covalent inhibitors structure-activity relationship insights and evolution perspectives","volume":"65","author":"La Monica","year":"2022","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/bs.enz.2025.07.005_bib0125","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202300116","article-title":"Discovery of potent pyrazoline-based covalent SARS-CoV-2 main protease inhibitors","volume":"24","author":"Moon","year":"2023","journal-title":"ChemBioChem"},{"issue":"4","key":"10.1016\/bs.enz.2025.07.005_bib0126","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00869-22","article-title":"Genetic surveillance of SARS-CoV-2 M(pro) reveals high sequence and structural conservation prior to the introduction of protease inhibitor paxlovid","volume":"13","author":"Lee","year":"2022","journal-title":"mBio"},{"issue":"2","key":"10.1016\/bs.enz.2025.07.005_bib0127","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245962","article-title":"A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease","volume":"16","author":"Baker","year":"2021","journal-title":"PLoS One"}],"container-title":["The Enzymes","Viral Proteases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874604725000216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874604725000216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T07:07:13Z","timestamp":1778828833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1874604725000216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443313967"],"references-count":127,"URL":"https:\/\/doi.org\/10.1016\/bs.enz.2025.07.005","relation":{},"ISSN":["1874-6047"],"issn-type":[{"value":"1874-6047","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}